Phase II Trial of Loubo®(Lobaplatin) and Pemetrexed for Patients with Metastatic Breast Cancer not Responding to Anthracycline or Taxanes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II Trial of Loubo®(Lobaplatin) and Pemetrexed for Patients with Metastatic Breast Cancer not Responding to Anthracycline or Taxanes

Published:2013-01-31 Issue:1 Volume:14 Page:413-417
ISSN:1513-7368
Container-title:Asian Pacific Journal of Cancer Prevention
language:en
Short-container-title:Asian Pacific Journal of Cancer Prevention

Author:

Deng Qian-Qian,Huang Xin-En,Ye Li-Hong,Lu Yan-Yan,Liang Yong,Xiang Jin

Publisher

Asian Pacific Organization for Cancer Prevention

Subject

Cancer Research,Public Health, Environmental and Occupational Health,Oncology,Epidemiology

Link

http://ocean.kisti.re.kr/downfile/crosscheck/apocp/JAKO201312855329514.pdf

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial;European Journal of Cancer;2024-01

2. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma;Journal of Cancer Research and Clinical Oncology;2023-11-20

3. A prospective phase II randomized study of docetaxel combined with lobaplatin versus TPF regimen induction chemotherapy sequential concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma;2023-08-18

4. The anti-tumor effects of the combination of microwave hyperthermia and lobaplatin against breast cancer cells in vitro and in vivo;Bioscience Reports;2022-02

5. Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial;Therapeutic Advances in Medical Oncology;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3